Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it has dosed the first subjects in a Phase 1/2a clinical trial of ARO-INHBE, the company’s investigational RNA interference (RNAi) ...
NONGPOH: A·doko skanggipa Ri Bhoi Park-ko ra·bana sianichi Ri Bhoi District namen kusi ong·na a·bachenganiko niknasienga. Ua park-na Mawtnum songo Meghalaya Industrial Development Corporation (MIDC) ...